New Swedish registry study
Uppsala, 12 October 2016. New Swedish registry study – a national collaboration between Senzime, Swedish Medtech, Skåne University Hospital in Lund and University of Gothenburg and the national quality registry for esophageal and gastric cancer.
A clinical trial investigating the OnZurf Probe for continuous, organ specific monitoring of lactate trends in postoperative esophageal cancer patients is ongoing in Lund. Esophageal cancer is a worldwide disease that affects about 500 000 patients annually. The clinical trial is being expanded in order to examine how the new OnZurf Probe solution may mitigate the healthcare costs associated with this disease. The results from the expanded study are expected to be published in the second quarter of 2017.
Senzime has developed user-friendly products for continuous measurement of glucose and lactate in different tissues. These measurements are often crucially important for post-surgical patients who are at risk of complications such as ischemia (lack of blood supply and oxygen) and anastomotic failure (in which bowel contents spill into the abdominal cavity), requiring extensive, lengthy and expensive treatment. Senzime’s product, the CliniSenz System, makes it possible to continuously monitor glucose and/or lactate from specific tissues and organs, thereby obtaining early-warning indications of potential complications.
To investigate the cost-saving potential of early detection of post-operative complications, Senzime has initiated a clinical collaboration with Swedish Medtech, Skåne University Hospital and University of Gothenburg to perform a clinical study of patients who have undergone esophageal resection (surgical removal of the cancer). This cooperation highlights opportunities and challenges focusing healthcare costs early in the development of a medical device. There is a dialogue with the Swedish TLV (the dental and pharmaceutical benefits agency) for study design and to transfer knowledge.
“This partnership will create a greater understanding of both health care costs and clinical solutions. We will now, in addition to the immediate and obviously important patient benefit, also be able to demonstrate the advantages of the CliniSenz System from an economic perspective and clearly illustrate how our products can contribute to improved health,” says Lena Söderström, CEO of Senzime AB.
For further information, please contact: Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com
TO THE EDITORS
About Senzime
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com